Profile data is unavailable for this security.
About the company
Grape King Bio Ltd is a Taiwan-based company mainly engaged in the manufacture and sale of healthcare products and beverages. The company operates through three business segments. The Direct Sales segment is engaged in the development and manufacture of related products for subsidiaries. The Distribution segment is engaged in the provision of own-brand products. The Original Equipment Manufacturer (OEM) segment is engaged in the OEM business in Taiwan and Shanghai. The main products include lactic acid bacteria products and other healthcare products, as well as beverage products, medicines and cosmetics. The Company operates in Taiwan, mainland China and other markets.
- Revenue in TWD (TTM)10.64bn
- Net income in TWD1.45bn
- Incorporated1971
- Employees501.00
- LocationGrape King Bio LtdNo. 60, Section 3, Lung-Kang RoadTAOYUAN 324TaiwanTWN
- Phone+886 34572121
- Fax+886 34572128
- Websitehttps://www.grapeking.com.tw/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Taidoc Technology Corp | 4.81bn | 1.02bn | 15.07bn | 829.00 | 14.87 | 1.70 | 11.77 | 3.13 | 10.62 | 10.62 | 50.22 | 92.98 | 0.3875 | 1.93 | 4.97 | -- | 8.49 | 17.60 | 10.91 | 22.98 | 43.12 | 50.73 | 21.90 | 28.49 | 2.56 | -- | 0.1054 | 68.99 | -50.07 | 2.03 | -69.93 | 3.02 | -34.71 | -2.62 |
| ScinoPharm Taiwan Ltd | 3.19bn | 287.06m | 22.38bn | 1.01k | 78.18 | 2.16 | 29.91 | 7.02 | 0.362 | 0.362 | 4.02 | 13.11 | 0.2696 | 1.46 | 4.48 | -- | 2.43 | 2.33 | 2.60 | 2.51 | 38.17 | 41.09 | 9.01 | 9.10 | 6.67 | -- | 0.0564 | 109.25 | -2.39 | -2.00 | -18.73 | -8.31 | 16.90 | -9.35 |
| Grape King Bio Ltd | 10.64bn | 1.45bn | 23.41bn | 501.00 | 16.21 | 2.35 | 9.03 | 2.20 | 9.75 | 9.75 | 71.40 | 67.36 | 0.6959 | 3.05 | 40.03 | -- | 14.01 | 15.14 | 21.43 | 23.59 | 80.26 | 81.20 | 20.14 | 20.50 | 1.47 | -- | 0.0163 | 70.39 | 2.35 | 2.98 | -0.3009 | 2.32 | -11.72 | 1.20 |
Data as of May 07 2024. Currency figures normalised to Grape King Bio Ltd's reporting currency: Taiwan Dollar TWD
7.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 05 Apr 2024 | 4.38m | 2.95% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 1.86m | 1.26% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 1.71m | 1.16% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 1.68m | 1.14% |
| Mellon Investments Corp.as of 04 Apr 2024 | 554.99k | 0.38% |
| BlackRock Advisors (UK) Ltd.as of 02 Apr 2024 | 355.00k | 0.24% |
| Quoniam Asset Management GmbHas of 30 Sep 2023 | 312.09k | 0.21% |
| SSgA Funds Management, Inc.as of 04 Apr 2024 | 193.66k | 0.13% |
| Schroder Investment Management North America, Inc.as of 29 Feb 2024 | 163.00k | 0.11% |
| RAM Active Investments SAas of 30 Jun 2023 | 151.91k | 0.10% |
More ▼
Data from 30 Jun 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
